Loading
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
NASDAQHealthcareBiotechnology
Latest quote
$0.8891
+$0.0455 · +5.39%
Previous close
$0.8891
+$0.0455 · +5.39%
Regular session · ET · Market data may be delayed.
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Day range
Current $0.8891
52-week range
Current $0.8891
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
42
Mixed
Risk
75
High Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Day range
Current $0.8891
52-week range
Current $0.8891
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1K USD | — | — | — | — |
| Gross profit | −1K USD | — | — | — | — |
| Research and development | 11.03M USD | 14.25M USD | 3.99K USD | 17.97K USD | 17.01K USD |
| Selling, general, and administrative | 10.9M USD | 13.86M USD | 11.36K USD | 9.68K USD | 9.6K USD |
| Operating expenses | 21.93M USD | 65.11M USD | 16.28K USD | 27.65K USD | 26.61K USD |
| Interest income | — | 400K USD | 600 USD | — | — |
| Depreciation and amortization | 1K USD | 63K USD | 119 USD | 169 USD | 121 USD |
| Operating income | −21.93M USD | −65.11M USD | −16.28K USD | −27.65K USD | −26.61K USD |
| Net income | −49.87M USD | −62.88M USD | −15.73K USD | −27.33K USD | −26.16K USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.00
574.84% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 11, 2022 | 1:20 | — | — |
Effective Nov 11, 2022
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
